Allopurinol

Generic Name: Allopurinol

Brand Names: Aloprim, Zyloprim

Drug Type: Small Molecule

Chemical Formula: C_₅H_₄N_₄O

CAS Number: 315-30-0

Unique Ingredient Identifier: 63CZ7GJN5I

Background: Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .
...

Indication: Allopurinol is indicated in :

1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
...

Associated Conditions: Hyperuricemia, Primary Gout, Recurrent calcium oxalate calculi, Secondary gout, Calcium oxalate calculi Renal Calculi

Associated Therapies: -

Clinical Trials

Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Phase 2

Completed

Conditions: Gout and Hyperuricemia

Interventions: Drug: RDEA3170
Drug: Placebo
Drug: Allopurinol

First Posted Date: 2014-03-05

Last Posted Date: 2019-09-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 204

Registration Number: NCT02078219

Locations: 🇯🇵
Research Site, Shinagawa-ku, Japan

A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL

Early Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia (ALL)

Interventions: Drug: Allopurinol

First Posted Date: 2014-01-28

Last Posted Date: 2022-06-21

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 34

Registration Number: NCT02046694

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Texas Children's Cancer and Hematology Centers, Houston, Texas, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

Center of Research Translation (CORT) Project 2

Phase 2

Completed

Conditions: JNC 7 Stage I Hypertension
Pre-hypertension

Interventions: Drug: Allopurinol
Drug: Placebo

First Posted Date: 2014-01-16

Last Posted Date: 2021-01-11

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 99

Registration Number: NCT02038179

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

Phase 3

Completed

Conditions: Coronary Artery Disease
Diabetic Nephropathies

Interventions: Drug: Placebo
Drug: Allopurinol

First Posted Date: 2013-12-20

Last Posted Date: 2020-12-04

Lead Sponsor: Alessandro Doria

Target Recruit Count: 530

Registration Number: NCT02017171

Locations: 🇨🇦
Mount Sinai Hospital / University of Toronto, Toronto, Ontario, Canada
🇺🇸
Emory University - Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Jacobi Medical Center, Bronx, New York, United States

and more 27 locations

Does Allopurinol Prolong a Treated, Acute Gout Flare?

Phase 4

Completed

Conditions: Gout

Interventions: Drug: allopurinol
Drug: Placebo (sugar pill)

First Posted Date: 2013-11-20

Last Posted Date: 2018-02-14

Lead Sponsor: 59th Medical Wing

Target Recruit Count: 35

Registration Number: NCT01988402

Locations: 🇺🇸
Wilford Hall Ambulatory Surgical Center, Lackland Air Force Base, Texas, United States

Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.

Phase 3

Completed

Conditions: Patients With Grade II Ankle Sprain

Interventions: Drug: Placebo
Drug: Allopurinol

First Posted Date: 2013-11-19

Last Posted Date: 2016-09-08

Lead Sponsor: Instituto de Investigacion Sanitaria La Fe

Target Recruit Count: 53

Registration Number: NCT01987570

Locations: 🇪🇸
University of Valencia, Valencia, Spain
🇪🇸
Hospital Universitari i Politècnic La Fe, Valencia, Spain

Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study

Phase 4

Completed

Conditions: End Stage Renal Disease
Left Ventricular Hypertrophy

Interventions: Drug: Allopurinol
Drug: Placebo (for allopurinol)

First Posted Date: 2013-09-26

Last Posted Date: 2016-11-04

Lead Sponsor: University of Dundee

Target Recruit Count: 80

Registration Number: NCT01951404

Locations: 🇬🇧
NHS Greater Glasgow and Clyde, Glasgow, La, United Kingdom
🇬🇧
NHS Tayside, Dundee, Tayside, United Kingdom
🇬🇧
NHS Ayrshire and Arran, Crosshouse, United Kingdom

Allopurinol in Acute Gout

Not Applicable

Withdrawn

Conditions: Gout

Interventions: Drug: allopurinol

First Posted Date: 2013-01-24

Last Posted Date: 2017-05-11

Lead Sponsor: Université de Sherbrooke

Registration Number: NCT01775098

A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Allopurinol
Drug: febuxostat

First Posted Date: 2012-11-29

Last Posted Date: 2014-10-29

Lead Sponsor: Astellas Pharma Taiwan, Inc.

Target Recruit Count: 109

Registration Number: NCT01736514

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

Phase 3

Completed

Conditions: Tumor Lysis Syndrome

Interventions: Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2012-11-09

Last Posted Date: 2014-11-02

Lead Sponsor: Menarini Group

Target Recruit Count: 346

Registration Number: NCT01724528

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy